Jan 13, 2014
New Phase 2 Clinical Data on Tokai Pharmaceuticals’ Galeterone in Advanced Prostate Cancer
CAMBRIDGE, Mass. — Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer and other hormonally driven cancers, today announced that new data from the ARMOR2 Phase 2 study of its lead drug candidate, galeterone (TOK-001), in patients with castration-resistant prostate cancer (CRPC) will be presented at the 2014 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco.
“We are very excited to share these new galeterone Phase 2 data in CRPC with the clinical oncology community at ASCO GU,” said Jodie Morrison, president and chief executive officer, Tokai Pharmaceuticals. “Based on clinical results to date, we believe that galeterone represents a promising potential new treatment option for CRPC patients and we look forward to advancing galeterone into late-stage clinical development later this year.”
The details of the poster presentation are as follows:
Date & Time: Thursday, January 30, 2014 from 11:30 a.m. to 1:00 p.m. and 5:15 p.m. to 6:45 p.m. (PT)
Title: ARMOR2: Galeterone in progressive CRPC patients who have failed oral therapy
Poster Board: E6
Session: General Poster Session A – Prostate Cancer
Location: Golden Gate Hall
Presenter: Mary-Ellen Taplin, M.D., associate professor of medicine, director of genitourinary clinical research, Dana-Farber Cancer Institute, Harvard Medical School, and co-principal investigator of ARMOR2
Following the meeting, the poster presentation will be available on the Tokai website atwww.tokaipharma.com.
Galeterone (TOK-001), is a first-in-class, multi-targeted, oral small molecule drug being developed for the treatment of castration-resistant prostate cancer (CRPC) that disrupts androgen receptor (AR) signaling, the key driver of CRPC, via three distinct mechanisms of action. Preclinical studies have shown that galeterone selectively inhibits CYP17 lyase to prevent testosterone synthesis, antagonizes testosterone binding to the androgren receptor (AR) and degrades the AR protein. Galeterone is the only drug in development or on the market that acts to degrade the AR protein, and that employs all three of these mechanisms in one compound to treat CRPC.
Tokai is investigating galeterone as part of the ARMOR (Androgen Receptor Modulation Optimized forResponse) clinical development program in patients with CRPC. Clinical proof-of-concept of galeterone in CRPC has been completed and results from the ongoing ARMOR2 Phase 2 trial will be used to define the Phase 3 trials planned for initiation in the second half of 2014.
About Tokai Pharmaceuticals
Tokai Pharmaceuticals is a biopharmaceutical company focused on developing new treatments for prostate cancer and other hormonally driven cancers. The company’s lead drug candidate, galeterone (TOK-001), is a first-in-class, multi-targeted, oral small molecule drug being developed for the treatment of patients with castration-resistant prostate cancer (CRPC). Based in Cambridge, Massachusetts, Tokai is backed by Apple Tree Partners and Novartis Venture Fund. For more information on the company and galeterone, please visit www.tokaipharma.com.All news about Tokai Pharmaceuticals